Literature DB >> 15637461

Direct comparison between two 1-84PTH assays in dialysis patients.

Junichiro J Kazama1, Suguru Yamamoto, Shigemi Kameda, Hiroki Maruyama, Ichiei Narita, Takashi Shigematsu, Fumitake Gejyo.   

Abstract

BACKGROUND/AIM: Today, two kinds of 1-84PTH assays are available in clinical practice. Few studies have directly compared the results of these assays in the same plasma.
METHODS: Plasma samples were collected from 235 dialysis patients and analyzed by the 1-84PTH-IRMA, intact PTH-IRMA, 1-84PTH-CLIA, and intact PTH-CLIA assays simultaneously.
RESULTS: The results obtained by the 1-84PTH-IRMA and 1-84PTH-CLIA were highly correlated to each other (r(2) = 0.971, p < 0.0001). In 90.2-92.3% of patients, the assays agreed when classifying them into three categories based on the K/DOQI guidelines. However, the 1-84PTH assays agreed in only 41.3-83.4% of patients when classifying them into two categories by calculating 1-84PTH/(intact PTH - 1-84PTH).
CONCLUSION: The results obtained by the two assays could be regarded as comparable in clinical practice. However, the 1-84PTH/(intact PTH-1-84PTH) ratio has to be carefully applied since it amplified the error of these assays. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15637461     DOI: 10.1159/000081788

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  2 in total

1.  Primary hyperparathyroidism: an overview.

Authors:  Jessica Mackenzie-Feder; Sandra Sirrs; Donald Anderson; Jibran Sharif; Aneal Khan
Journal:  Int J Endocrinol       Date:  2011-06-02       Impact factor: 3.257

2.  Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy.

Authors:  Ryo Koda; Junichiro James Kazama; Koji Matsuo; Kazuko Kawamura; Suguru Yamamoto; Minako Wakasugi; Tetsuro Takeda; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2014-11-11       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.